Pharmacokinetics Study of Asciminib in Subjects With Impaired Renal Function Compared to Matched Healthy Volunteers

Inclusion Criteria: * Male or sterile / post-menopausal female * BMI between 18 and 36 kg/m2, body weight greater than or equal to 50 kg and no more than 120 kg * Adequate venous access for blood sampling * For healthy volunteers: subject must be matched to at least one renal impaired subject by age (+/- 10 years), body weight (+/- 20%) and gender * For renal impaired subjects: documented stable renal disease without evidence of progressive decline in renal function (stable renal disease is defined as no significant change, such as, stable aGFR \< 90, for 12 weeks prior to study entry) Exclusion Criteria: * women of child-bearing potential / pregnant / nursing * contraindication or hypersensitivity to any drug or metabolites from similar class as asciminib or to any excipients of the study drug * cardiac or cardiac repolarization abnormality * history of psychiatric illness within the past 2 years * history of acute or chronic pancreatitis * subject on dialysis * smokers (use of tobacco products in the previous 3 months) and not willing to abstain from using tobacco during the study * any surgical or medical condition altering the absorption, distribution, metabolism or excretion of drug * history of immunodeficiency diseases, including a positive Human Immunodeficiency Virus (HIV) test result at screening * chronic infection with Hepatitis B virus (HBV) or Hepatitis C virus (HCV) at screening * donation or loss of 400 mL or more of blood or plasma within 8 weeks prior to dosing or other amount considered to compromise the health of the subject if previous history of anemia exists * use of the following drugs within 28 days prior to dosing: drugs that prolong the QT interval; CYP3A4 inhibitors and inducers; BCRP, UGT and PgP inhibitors and inducers Other protocol-defined inclusion/exclusion criteria may apply